Device profile of the Mobi-C artificial cervical disc: an overview of its safety and efficacy.

Abstract

Introduction: The Mobi-C Cervical Disc Replacement is a motion preserving alternative to anterior cervical discectomy and fusion in properly indicated patients. In 2013, Mobi-C became the first cervical disc in the United States approved to treat more than one level of the cervical spine. The FDA determined Mobi-C to be statistically superior to fusion at two levels, based on the primary endpoint of a prospective, concurrently controlled and randomized multicenter clinical trial.

Areas covered: The history of Mobi-C and cervical disc arthroplasty is discussed. The unique biomechanics and structure of Mobi-C, the clinical results, the long term follow-up, the disc's biomechanics, and cost-effectiveness research are described. The competitive landscape is overviewed.

Expert opinion: The evidence in this article supports the use of the Mobi-C cervical disc prosthesis as a viable alternative to fusion surgery in selected patients. Mobi-C has a relatively long track record compared to most other cervical disc prostheses. Thus far, Mobi-C is a very good option for preserving cervical motion based on long term follow-up, for achieving favorable clinical outcomes, and for maintaining patient safety. The Mobi-C cervical disc prosthesis is generally viewed positively, supported by clinical experience and research findings.